ERBB2 and breast carcinoma: When looking at HR+ ABC patients categorized by HER2 status, patients with HER2 negative breast cancer were more likely to receive initial ET compared with HER2 positive patients (23.3 vs 18.7%, P = 0.038) (Supplementary Figure 1).